1. Home
  2. RQI vs RARE Comparison

RQI vs RARE Comparison

Compare RQI & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Steers Quality Income Realty Fund Inc

RQI

Cohen & Steers Quality Income Realty Fund Inc

HOLD

Current Price

$13.07

Market Cap

1.8B

Sector

Finance

ML Signal

HOLD

Logo Ultragenyx Pharmaceutical Inc.

RARE

Ultragenyx Pharmaceutical Inc.

HOLD

Current Price

$23.86

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RQI
RARE
Founded
2002
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
2.1B
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
RQI
RARE
Price
$13.07
$23.86
Analyst Decision
Strong Buy
Analyst Count
0
19
Target Price
N/A
$59.95
AVG Volume (30 Days)
322.9K
1.7M
Earning Date
01-01-0001
05-04-2026
Dividend Yield
8.20%
N/A
EPS Growth
N/A
7.31
EPS
N/A
N/A
Revenue
N/A
$673,000,000.00
Revenue This Year
N/A
$13.12
Revenue Next Year
N/A
$37.80
P/E Ratio
N/A
N/A
Revenue Growth
N/A
20.13
52 Week Low
$11.30
$18.29
52 Week High
$13.39
$40.17

Technical Indicators

Market Signals
Indicator
RQI
RARE
Relative Strength Index (RSI) 60.11 54.67
Support Level $12.15 $20.11
Resistance Level $13.38 $25.70
Average True Range (ATR) 0.18 1.07
MACD 0.04 0.06
Stochastic Oscillator 74.62 40.78

Price Performance

Historical Comparison
RQI
RARE

About RQI Cohen & Steers Quality Income Realty Fund Inc

COHEN & STEERS QUALITY INCOME REALTY FUND INC is a diversified, closed-end management investment company. The primary investment objective of the fund is high current income through investment in real estate securities. Its secondary objective is capital appreciation. The Fund invests at least its total assets in income-producing common stocks and other securities issued by real estate companies, such as real estate investment trusts under normal market conditions.

About RARE Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.

Share on Social Networks: